Bibliografía del artículo
1. Jemal A, Siegel R, Ward E y col. Cancer statistics 2006. CA Cancer J Clin 2006; 56:106-30.
2. Martínez García C, Peris Bonet R, Sánchez Pérez M. Epidemiología descriptiva del cáncer en España. En: FESEO (ed.) Libro Blanco de Oncología en España, Ergon, Madrid, 2002.
3. Andre T, Louvet C, De Gramont A. Colon cancer: what is new in 2004? Bull Cancer 2004; 91:75-80.
4. Franklin ME Jr, Rosenthal D, Abrego Medina D y col. Prospective comparison of open vs. laparoscopic colon surgery for carcinoma. Five-year results. Dis Colon Rectum 1996; 39:S35-S46.
5. Andre T, Boni C, Mounedji-Boudiaf L y col. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-51.
6. Brown ML, Nayfield SG, Shibley LM. Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst 1994; 86:424-30.
7. O'Connell MJ. Current status of adjuvant therapy for colorectal cancer. Oncology (Huntingt) 2004; 18:751-5.
8. Akbulut H, Altuntas F, Akbulut KG y col. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine 2002; 20:184-90.
9. Bhatavdekar JM, Patel DD, Chikhlikar PR y col. Molecular markers are predictors of recurrence and survival in patients with Dukes B and Dukes C colorectal adenocarcinoma. Dis Colon Rectum 2001; 44:523-33.
10. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 88:1739-57.
11. Kahlenberg MS, Sullivan JM, Witmer DD, Petrelli NJ. Molecular prognostics in colorectal cancer. Surg Oncol 2003; 12:173-86.
12. Reiter W, Stieber P, Reuter C y col. Preoperative serum levels of CEA and CA 19-9 and their prognostic significance in colorectal carcinoma. Anticancer Res 1997; 17:2935-8.
13. Andre T, Boni C, Mounedji-Boudiaf L y col. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350:2343-51.
14. Andre T, Sargent D, Tabernero J y col. Current Issues in Adjuvant Treatment of Stage II Colon Cancer. Ann Surg Oncol 2006.
15. Calvo E, Cortés J, Rodríguez J y col. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. Clin Colorectal Cancer 2002; 2:104-10.
16. Douillard JY, Cunningham D, Roth AD y col. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355:1041-7.
17. Hurwitz H, Fehrenbacher L, Novotny W y col. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
18. Cunningham D, Humblet Y, Siena S y col. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-45.
19. Bick RL. Alterations of hemostasis associated with malignancy: etiology, pathophysiology, diagnosis and management. Semin Thromb Hemost 1978; 5:1-26.
20. Páramo JA, Lecumberri R, Orbe J. Mecanismos fibrinolíticos y tratamiento en las neoplasias hematológicas. Hematol Citocinas Inmunoter Ter Cel 2002; 5:103-14.
21. Páramo J, Campbell W, Cuesta B, Gómez C, Aranda A, Rocha E. Fibrinolytic response in malignancy. Fibrinolysis 1987; 1:195-9.
22. Rickles FR, Edwards RL, Barb C, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth. Cancer 1983; 51:301-7.
23. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983; 62:14-31.
24. Sorensen HT, Mellemkjaer L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338:1169-73.
25. Baker EA, Leaper DJ. The plasminogen activator and matrix metalloproteinase systems in colorectal cancer: relationship to tumour pathology. Eur J Cancer 2003; 39:981-8.
26. Cubo T, Padilla D, De la Osa G y col. Serum vascular endothelial growth factor levels in patients with colorectal cancer and its prognostic significance. Med Clin (Barc ) 2004; 122:201-4.
27. Damin DC, Rosito MA, Gus P, Roisemberg I, Bandinelli E, Schwartsmann G. Von Willebrand factor in colorectal cancer. Int J Colorectal Dis 2002; 17:42-5.
28. Guba M, Seeliger H, Kleespies A, Jauch KW, Bruns C. Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis 2004.
29. Montemurro P, Conese M, Altomare DF, Memeo V, Colucci M, Semeraro N. Blood and tissue fibrinolytic profiles in patients with colorectal carcinoma. Int J Clin Lab Res 1995; 25:195-200.
30. Seetoo DQ, Crowe PJ, Russell PJ, Yang JL. Quantitative expression of protein markers of plasminogen activation system in prognosis of colorectal cancer. J Surg Oncol 2003; 82:184-93.
31. Van Duijnhoven EM, Lustermans FA, van Wersch JW. Evaluation of the coagulation/fibrinolysis balance in patients with colorectal cancer. Haemostasis 1993; 23:168-72.
32. Xu G, Zhang YL, Huang W. Relationship between plasma D-dimer levels and clinicopathologic parameters in resectable colorectal cancer patients. World J Gastroenterol 2004; 10:922-3.
33. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997; 90:3167-72.
34. Karayiannakis AJ, Syrigos KN, Polychronidis A y col. Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery. Ann Surg 2002; 236:37-42.
35. Wartiovaara U, Salven P, Mikkola H y col. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb Haemost 1998; 80:171-5.
36. Seghatchian M, Savidge G. Factor VIII-von Willebrand factor. CRC Press, London, 1989.
37. Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285:L20-L28.
38. Giorno R. A comparison of two immunoperoxidase staining methods based on the avidin-biotin interaction. Diagn Immunol 1984; 2:161-6.
39. Guesdon JL, Ternynck T, Avrameas S. The use of avidin-biotin interaction in immunoenzymatic techniques. J Histochem Cytochem 1979; 27:1131-9.
40. Hosmer DW, Lemeshow S. Applied survival analysis: regression modeling of time to event data, John Wiley and Sons, New York, 1999.
41. Ferlay J, Bray F, and Pisani P. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide, version 1.0. World Health Organization. IARC. CancerBase 5 . 2001. Lyon, IARCPress.
42. Saltz LB, Meropol NJ, Loehrer PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-8.
43. Fernando NH, Hurwitz HI. Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 2004; 9 Suppl 1:11-8.
44. Verheul HM, Pinedo HM. Vascular endothelial growth factor and its inhibitors. Drugs Today (Barc ) 2003; 39(Suppl C):81-93.
45. George ML, Eccles SA, Tutton MG, Abulafi AM, Swift RI. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 2000; 6:3147-52.
46. Verheul HM, Hoekman K, Luykx-de Bakker S y col. Platelet: transporter of vascular endothelial growth factor. Clin Cancer Res 1997; 3:2187-90.
47. Verheul HM, Pinedo HM. Tumor growth: A putative role for platelets? Oncologist 1998; 3:II.
48. Verheul HM, Jorna AS, Hoekman K, Broxterman HJ, Gebbink MF, Pinedo HM. Vascular endothelial growth factor-stimulated endothelial cells promote adhesion and activation of platelets. Blood 2000; 96:4216-21.
49. Werther K, Christensen IJ, Nielsen HJ. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002; 62:343-50.
50. Bajou K, Masson V, Gerard RD y col. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001; 152:777-84.
51. Devy L, Blacher S, Grignet-Debrus C y col. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002; 16:147-54.
52. Ho CH, Yuan CC, Liu SM. Diagnostic and prognostic values of plasma levels of fibrinolytic markers in ovarian cancer. Gynecol Oncol 1999; 75:397-400.
53. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43(Suppl):S42-S51.
54. Mandriota SJ, Seghezzi G, Vassalli JD y col. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995; 270:9709-16.
55. Mandriota SJ, Pepper MS. Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factor. J Cell Sci 1997; 110(Pt 18):2293-302.
56. Stefansson S, McMahon GA, Petitclerc E, Lawrence DA. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des 2003; 9:1545-64.
57. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999; 13:781-92.
58. Berglund A, Molin D, Larsson A, Einarsson R, Glimelius B. Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma. Ann Oncol 2002; 13:1430-7.
59. Broll R, Erdmann H, Duchrow M y col. Vascular endothelial growth factor (VEGF)--a valuable serum tumour marker in patients with colorectal cancer? Eur J Surg Oncol 2001; 27:37-42.
60. Chin KF, Greenman J, Gardiner E, Kumar H, Topping K, Monson J. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 2000; 83:1425-31.
61. Chin KF, Greenman J, Reusch P, Gardiner E, Marme D, Monson JR. Vascular endothelial growth factor and soluble Tie-2 receptor in colorectal cancer: associations with disease recurrence. Eur J Surg Oncol 2003; 29:497-505.
62. De Vita F, Orditura M, Lieto E y col. Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer 2004; 100:270-8.
63. Duff SE, Li C, Jeziorska M y col. Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 2003; 89:426-30.
64. Fujisaki K, Mitsuyama K, Toyonaga A, Matsuo K, Tanikawa K. Circulating vascular endothelial growth factor in patients with colorectal cancer. Am J Gastroenterol 1998; 93:249-52.
65. Hyodo I, Doi T, Endo H y col. Clinical significance of plasma vascular endothelial growth factor in gastrointestinal cancer. Eur J Cancer 1998; 34:2041-5.
66. Ikeda M, Furukawa H, Imamura H y col. Surgery for gastric cancer increases plasma levels of vascular endothelial growth factor and von Willebrand factor. Gastric Cancer 2002; 5:137-41.
67. Karayiannakis AJ, Syrigos KN, Zbar A y col. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery 2002; 131:548-55.
68. Landriscina M, Cassano A, Ratto C y col. Quantitative analysis of basic fibroblast growth factor and vascular endothelial growth factor in human colorectal cancer. Br J Cancer 1998; 78:765-70.
69. Lissoni P, Rovelli F, Malugani F, Brivio F, Fumagalli L, Gardani GS. Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer. Int J Biol Markers 2003; 18:152-5.
70. Takeda A, Shimada H, Imaseki H, Okazumi S, Natsume T, Suzuki T, Ochiai T. Clinical significance of serum vascular endothelial growth factor in colorectal cancer patients: correlation with clinicopathological factors and tumor markers. Oncol Rep 2000; 7:333-8.
71. Werther K, Christensen IJ, Nielsen HJ. Prognostic impact of matched preoperative plasma and serum VEGF in patients with primary colorectal carcinoma. Br J Cancer 2002; 86:417-23.
72. Werther K, Sorensen S, Christensen IJ, Nielsen HJ. Circulating vascular endothelial growth factor six months after primary surgery as a prognostic marker in patients with colorectal cancer. Acta Oncol 2003; 42:837-45.
73. Duffy MJ, van Dalen A, Haglund C y col. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003; 39:718-27.
74. Yuste AL, Aparicio J, Segura A y col. Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy. Clin Colorectal Cancer 2003; 2:231-4.
75. Blackwell K, Hurwitz H, Lieberman G y col. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer 2004; 101:77-82.
76. Nielsen HJ, Christensen IJ, Sorensen S, Moesgaard F, Brunner N. Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group. Ann Surg Oncol 2000; 7:617-23.
77. Edwards CM, Warren J, Armstrong L, Donnelly PK. D-dimer: a useful marker of disease stage in surgery for colorectal cancer. Br J Surg 1993; 80:1404-5.
78. Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol 2001; 31:388-94.
79. Oya M, Akiyama Y, Yanagida T, Akao S, Ishikawa H. Plasma D-dimer level in patients with colorectal cancer: its role as a tumor marker. Surg Today 1998; 28:373-8.
80. Unsal E, Atalay F, Atikcan S, Yilmaz A. Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med 2004; 98:93-8.
81. Schwartsmann G, Damin DC, Roisemberg I. Malignant disease and von Willebrand factor. Lancet Oncol 2001; 2:716-7.
82. Wang WS, Lin JK, Lin TC y col. Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma. World J Gastroenterol 2005; 11:2166-70.
83. Gil Bazo I, Díaz González JA, Rodríguez J y col. Role of von Willebrand factor levels in the prognosis of stage IV colorectal cancer: do we have enough evidence? World J Gastroenterol 2005; 11:6072-3.
84. Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003; 30:39-50.
85. Folprecht G, Kohne CH. The role of new agents in the treatment of colorectal cancer. Oncology 2004; 66:1-17.
86. Kabbinavar F, Hurwitz HI, Fehrenbacher L y col. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21:60-5.
87. Willett CG, Boucher Y, di Tomaso E y col. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10:145-7.